Valantine Hannah's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Mar 3, 2026
- Accession no.
- 0001470831-26-000236
- Filed
- Mar 3, 2026
- Trade date
- Feb 27, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.72M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Valantine HannahCIK 0001855608 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | MOption exerciseAcquired | +25,484 | $48.45 | +$1,234,699.8 | 32,949 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −14,584 | $67.08F2 | −$978,294.72 | 18,365 | Direct | |
| Feb 27, 2026 | Common Stock | SSaleDisposed | −10,900 | $67.84F3 | −$739,456 | 7,465 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | MOption exerciseDisposed | −25,484 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.